References

n.d. [https://www.mstrust.org.uk/a-z/expanded-disability-status-scale-edss.

n.d. https://www.mstrust.org.uk/a-z/expanded-disability-status-scale-edss.

n.d. https://clinicaltrials.gov/ct2/show/NCT03073603.

n.d. https://en.wikipedia.org/wiki/Deductive_reasoning.

n.d. https://en.wikipedia.org/wiki/Confounding.

n.d. https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Fatigue.

n.d. sourcezoneja.wordpress.com.

n.d. https://en.wikipedia.org/wiki/Inflammation.

2017. A look at disease modifying therapies for multiple sclerosis. Feb. www.icer-review.org.

Alam SM et al. 1993. “Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.” J Neurol Neurosurg Psychiatry 56 (11): 1219-20.

Amato MP, Ponziani G, Siracusa G, Sorbi S. 2001. “Cognitive Dysfunction in Early-Onset Multiple Sclerosis: A Reappraisal After 10 Years.” Arch Neurol 58 (10): 1602–1606.

Barnes D et al. 1997. “Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.” Lancet 349 (9056): 902-6.

Belk, O et al. 2019. “Changes in the risk of reaching multiple sclerosis disability milestones in recent decades , A population -based cohort study in Sweden.” JAMA Neurol 76 (6): 665-671.

Brex P, Williams V. 2018. ACNR 18 (2): 14-16.

Brownlee et al. 2017. Lancet 389: 1336-46.

Chaflin SB, Broadley S, Taylor BV. 2018. “The effect of disease-modifying therapies on disability progression in MS: a systematic overview of meta analysis.” Front Neurol 9: 1150.

Chiaravalloti, Nancy D, and John Deluca. 2008. “Cognitive Impairment in multiple sclerosis.” Lancet Neurol 7: 1139-51.

Cocco et al. 2015. MS Journal 21 (4): 433 – 441.

Compston A, Coles A. 2008. “Multiple sclerosis.” Lancet 372 (9648): 1502-17. doi:10.1016/S0140-6736(08)61620-7.

Confavreux, C, and S Vukusic. 2014. The clinical course of multiple sclerosis. Vol. 122, chap. 15 in Handbook of Clinical Neurology, Multiple Sclerosis and Related Disorders, by Editor D.S. Goodin, 343-369. Elsevier B.V.

Consortium of MS Centers. 2018. “MRI Protocols and Clinical Guidelines for the diagnosis and followup of MS 2018 REVISED GUIDELINES.” https://cdn.ymaws.com/mscare.site-ym.com/resource/collection/9C5F19B9-3489-48B0-A54B-623A1ECEE07B/2018MRIGuidelines_booklet_with_final_changes_0522.pdf.

Douglas S Goodin, Anthony Traboulsee, Volker Knappertz, Anthony T Reder, David Li2, Dawn Langdon, Christian Wolf, Karola Beckmann, Andreas Konieczny, George C Ebers, for the 16-Year Long Term Follow-up Study Investigators. 2012. “Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.” J Neurol Neurosurg Psychiatry 2012;83:282e287. 83: 282-7.

Ebers, G. 1998. ““Natural History of MS.” In McAlpine’s MS 3d edition, ch 6.

G C Ebers, A Traboulsee, D Li, D Langdon, A T Reder, D S Goodin, T Bogumil,K Beckmann, C Wolf, A Konieczny, for the Investigators of the 16-year Long-Term folllowup study. 2010. “Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.” J Neurol Neurosurg Psychiatry 81: 907-912. Accessed June 25, 2020. doi:. doi:10.1136/jnnp.2009.204123.

Green, Ari J. 2019. “Potential Benefits of Early Aggressive Treatment in Multiple Sclerosis.” JAMA Neurology 76 (3): 254-256.

Harding et al. 2019. “Clinical Outcomes of escalation vs early intensive disease modifying therapy in patients with Multiple Sclerosis.” Jama Neurology 75 (5): 536-541.

Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. 1991. “Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.” Ann Neurol 29 (5): 548-55.

Jacqueline F. Marcus, MD1 and Emmanuelle L. Waubant, MD, PhD. 2013 . “Updates on Clinically Isolated Syndrome and Diagnostic Criteria for Multiple Sclerosis.” Neurohospitalist 3 (2): 65–80.

Jeffrey A. Cohen, Nadia Tenenbaum, Alit Bhatt , Ying Zhang and Ludwig Kappos. 2019. “Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results.” Ther Adv Neurol Disord 12: 1–16.

Marcus Koch, Elaine Kingwell, Peter Rieckmann, Helen Tremlett, UBC MS Clinic. 2010. “The natural history of secondary progressive multiple sclerosis.” J Neurol Neurosurg Psychiatry 81: 1039-1043. Accessed 6 23, 2020. doi: doi:10.1136/jnnp.2010.208173.

Markowitz, CE. 2014. “Multiple sclerosis update.” Int J MS Care Vol 16 (Suppl 4): 5-11.

1993. “Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.” J Neuro Neurosurg Psychiatry 1219-20.

Multiple Sclerosis Trust. 2017. Does benign MS stay benign MS? July 13. mstrust.org.uk.

Murray, T Jock. 2005. “Searching for therapy.” In Multiple sclerosis: the history of a disease, by T Jock Murray, Chapter 15. NY: Demos Health.

Palladino R, Marrie RA, Majeed A, Chataway J. 2020. “Evaluating the risk of microvascular events and mortality among people with multiple sclerosis in England.” Jama Neurol (EPUB 2020 May 4).

Rae-Grant A, et al. 2018. “Practice guidelines recommendation summary. Disease-modifying therapy for adults with Multiple Sclerosis.” Neurology 90: 777-788.

Rao, S, G Leo, L Bernardino, and F Unverzagt. 1991. “Cognitive dysfunction in multiple sclerosis: frequency, patterns. and predictions.” Neurology 41: 685-91.

Rose, AS, JW Kuzma, JF Kurtzke, NS Namerow, WA Sibley, and WW Tourtellotte. 1970. “Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs placebo – finalreport.” Neurology 20: 1-59.

Rover C et al. 2015. “Changing EDSS progression in placebo cohorts in relapsing MS: a systematic review and meta-regression.” PLoS One 10 (9).

Rover C, Nicholas R, Straube S, et al. 2015. “Changing EDSS progression in placebo cohorts in relapsing MS: A systematic review and meta-regression.” PLoS ONE 10 (1): e0137052.

Sartori, Arianna, Mohammad Abdoli , and Mark S Freed. 2017. “Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.” J Neurol 264 (6): 1068-1075.

Steinworth et al. 2013. “Explaining temporal trends in annualized relapse rates in placebo groups of randomizes controlled trials in relapsing-remitting MS: systemic review and meta-regression.” Mult Scler 19 (12): 1580-1586.

Swanton, Josephine, Kryshani Fernando, and David Miller. 2014 . Early prognosis of multiple sclerosis. Vol. 122 (3rd series), in Handbook of Clinical Neurology, by D S Goodin, edited by D S Goodin, 371-391. Ansterdam: Elsevier B.V.

Tedeholm et al. 2012. MS Journal 19 (6): 765-774.

Thompson AJ, Banwell BL, Barkhof F, et al. 2018. ” Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.” Lancet Neurol 17: 162–173.

Trojano et al. 2007. “New natural history of interferon-B-treated relapsing multiple sclerosis.” Ann Neurol 61 (4): 300-306.

Tsirgoulis et al. 2014.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. 2012. Principles of Epidemiology. Third Edition. Atlanta: Centers for Disease Control and Prevention (CDC).

Uitdehaag, van Munster CEP &. 2017. “Outcome measures in clinical trials for Multiple Sclerosis.” CNS Drugs 31: 217-236.

Weiner, Stanliewiez &. 2020.

William, J et al. 2019. “Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive.” JAMA 321 (2): 175-187.

Wingerchuk, Dean M , and Brian G Weinshenke. 2016. “Disease modifying therapies for relapsing multiple sclerosis.” BMJ 354: i3518.